# A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Study · id `cardio:ct-nct06679946` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06679946](<https://clinicaltrials.gov/study/NCT06679946>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06679946

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 700 participants.

## Technical summary

Registry record NCT06679946. Allocation not applicable; no masking; primary purpose treatment. Start 2024-12-03 (actual); primary completion 2028-03-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 700 participants (planned count; ClinicalTrials.gov record NCT06679946, source copy `cardio:ctgov-nct06679946-2026-10-21`, retrieved 2026-10-31)
- Started: 2024-12-03 (actual) (ClinicalTrials.gov record NCT06679946, source copy `cardio:ctgov-nct06679946-2026-10-21`, retrieved 2026-10-31)
- Primary completion: 2028-03-31 (anticipated) (ClinicalTrials.gov record NCT06679946, source copy `cardio:ctgov-nct06679946-2026-10-21`, retrieved 2026-10-31)
- Completion: 2028-03-31 (anticipated) (ClinicalTrials.gov record NCT06679946, source copy `cardio:ctgov-nct06679946-2026-10-21`, retrieved 2026-10-31)
- Countries: United States; Argentina; Austria; Belgium; Brazil; Czechia; Denmark; France; Italy; Netherlands; Norway; Portugal; South Korea; Spain; Sweden; Taiwan; United Kingdom (ClinicalTrials.gov record NCT06679946, source copy `cardio:ctgov-nct06679946-2026-10-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06679946-2026-10-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Condition: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Intervention (Drug): Vutrisiran
- Lead sponsor: Alnylam Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`)
- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Alnylam Pharmaceuticals (`cardio:org-alnylam-pharmaceuticals`)

## Provenance

Content hash: 8a9a0da902607392bb9f4ba01638b76fbacf2e2d2121260ec127c699f58668c6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
